NCT00158912已完成4 期
Ventricular Arrhythmia Suppression Trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 550
- 主要终点
- The primary endpoint for this study will be the number of episodes of ventricular tachyarrhythmia in each patient during each follow-up period (ON vs. OFF treatment).
研究概览
简要总结
The purpose of VAST is to determine whether the Rate Smoothing feature in Guidant's PRIZM/VITALITY-family ICDs has an effect on the incidence of ventricular tachyarrhythmias.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who receive a commercially available Guidant PRIZM, PRIZM 2, or VITALITY AVT ICD
- •Patients who sign and date a Patient Informed Consent prior to study enrollment
- •Patients who remain in the clinical care of physicians of their implanting center
排除标准
- •Patients who have chronic atrial fibrillation. Paroxysms of AF are not an exclusion criterion, but the patient must be in normal sinus rhythm at the time of randomization. If history of AF is unknown or uncertain, or the patient was recently cardioverted, there must be at least 23 hours of normal sinus rhythm within the 24 hour period preceding randomization
- •Patients who previously had an ICD
- •Patients with current indications for cardiac resynchronization therapy with defibrillation (CRT-D)
- •Patients whose life expectancy is less than 12 months due to other medical conditions
- •Patients who are expected to receive a heart transplant during the duration of the study
- •Patients who have or who are likely to receive a tricuspid or other valve prosthesis
- •Patients who are currently enrolled in another investigational study of active medical therapy. Each instance should be brought to Guidant's Clinical Application Research Studies (CARS) group to determine eligibility
- •Patients who are younger than 18 years of age
- •Patients who are mentally incompetent and cannot give a Patient Informed Consent or participate in the study
结局指标
主要结局
The primary endpoint for this study will be the number of episodes of ventricular tachyarrhythmia in each patient during each follow-up period (ON vs. OFF treatment).
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
Ventricular Pacing Rate in Follow-up of Patients Treated With Definitive PM Implantation Post TAVIConduction Defect, CardiacAortic StenosisNCT06499428I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio67
已完成
不适用
Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicNCT03450252Barts & The London NHS Trust17
已完成
4 期
VERRARI - "Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?"Ventricular FibrillationNCT00180427Guidant Corporation75
已完成
不适用
EVITA: Evaluation of VIP Feature in Pacemaker PatientsArrhythmiaNCT00366158Abbott Medical Devices461
终止
不适用
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial FibrillationAtrial FibrillationVentricular TachycardiaNCT06647459Vanderbilt University Medical Center32